“We provide unparalleled expertise in collaborating with our clients on oncology drug development and commercialization.”
NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the U.S., but work hard to maintain easy access and all the efficiencies of a smaller operation.
NeoGenomics has been serving the cancer community for over 12 years. We welcomed the expertise of our peers at Clarient Diagnostic Services through the acquisition of that company in December 2015.
NeoGenomics Laboratories is comprised of a national team of experts in developing and delivering laboratory diagnostic and clinical trial services with a focus on cancer. Our staff physicians, scientists, laboratory professionals, client services representatives, and salespeople team up with our clients. Together, we work to solve the medical, scientific, and logistical challenges of making precise diagnoses, aiding in bringing new therapies to market and finding the unique hallmarks of each patient’s disease that point the way to proper treatment.
We provide expert bone marrow and surgical pathology consults; cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor FISH testing with the largest menu of technical-only services available; 10-color flow cytometry; histology supported by an extensive IHC antibody library; and >160 molecular oncology tests comprising the most comprehensive combination of multi-method tumor profiles and targeted biomarker tests in the industry. Our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out FISH, flow cytometry, and/or IHC. Our Pharma Services division offers all of these methodologies along with other technology platforms to provide laboratory services that meet the rapidly evolving needs of our clients. Through our differentiators of expertise, flexibility, and scalability we partner with our clients to develop better, more effective drugs.
Why it matters?
People with cancer need more options, and we believe precision medicine is a critical component in controlling cancer. With all testing methodologies in one laboratory system, we have the ability to interrogate blood-based cancer or solid tumor by as many means necessary to reveal biomarkers that expose that disease’s susceptibilities to standard or novel therapies. NeoGenomics’ extremely fast test development cycle means we are highly responsive to guideline changes and new therapy options. Design of our new tests always involves a balance of convention and innovation so costs are reduced and results become available promptly.
It all comes back to the patients. Time and results mean everything to our patients, and we keep that first in our minds.
NeoGenomics Pharma Services
With NeoGenomics’ acquisition of Clarient, NeoGenomics’ Pharma Services division now offers a wider range of service offerings and provide an even higher level of support to our clients. Whether you need a custom assay developed or would like to use one of its clinically validated tests, the firm can help advance your clinical trial.
NeoGenomics Pharma Services has developed tools to help its clients with their clinical trial and research laboratory service needs. Whether you need custom biomarker development or would like to use an assay from our robust clinical menu, we can help. With over a decade of experience, we are one of the fastest growing and innovative companies in the biotech space. We are known for pioneering new technologies, like our tech-only offerings, that help clients reduce costs and provide greater flexibility to analyze data.
Personalized medicine is an evolving field in which treatments are tailored to the individual patient. The FDA requires a companion diagnostic test (CDx) if a new drug works on a specific genetic or biological target that is present in some, but not all, patients with certain cancer. The CDx identifies which patients would benefit from the use of, or who could be harmed by the use of a certain drug for treatment of their disease.
The CDx process works best when the development of the test begins before the drug enters clinical trials. Early collaborations between pharmaceutical companies, test manufacturers, and laboratory services can result in faster access to promising new treatments for cancer patients. NeoGenomics’ CDx Pharma Services works with 6 of the 10 manufacturers of FDA-cleared Companion Diagnostic Devices (In Vitro and Imaging Tools)* for convenient and fast CDx transfer and validations. NeoGenomics offers several FDA-Approved Assays and FDA-Cleared Assays for research and clinical use.
NeoGenomics’ Pharma Services offers a wide variety of assays utilizing FDA-Approved and FDA-Cleared assays and instruments on multiple modalities to help accelerate your drug development. All tests listed have been clinically validated in our laboratories and are available for research or clinical use.
Douglas M. VanOort, Chairman of the Board of Directors and CEO: VanOort has served as the Chairman of the Board of Directors and Chief Executive Officer of NeoGenomics since October 28, 2009. For seven months prior to October 2009, he served as Chairman of the Board of Directors, Executive Chairman, and Interim Chief Executive Officer. Prior to joining NeoGenomics, Mr. VanOort was a General Partner with a private equity firm and a Founding Managing Partner of a venture capital firm. From 1982 through 1999, Mr. VanOort served in various positions at Corning Incorporated and at its spin-off company, Quest Diagnostics, Inc. During the period from 1995 through 1999, he served as the Senior Vice President Operations for Quest Diagnostics, Inc. which was then a $1.5 billion newly formed NYSE-traded Company. During the period of 1989 to 1995, he held senior executive positions at Corning Life Sciences, Inc., including Executive Vice President. Corning Life Sciences Inc. had revenues of approximately $2 billion and was spun-off in a public transaction to create both Quest Diagnostics and Covance, Inc. From 1982 to 1989, Mr. VanOort served in various executive positions at Corning Incorporated, including Director of Mergers & Acquisitions. Mr. VanOort currently serves as a member of the Board of Directors of several privately-held companies and is a principal owner of a privately-held retail hardware store chain. Mr. VanOort is a graduate of Bentley University.